Evidence map›Paper›PMID 35118481›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time.

Lauren E Gentles, Leanne Kehoe, Katharine H D Crawford, Kirsten Lacombe, Jane Dickerson, Caitlin Wolf, Joanna Yuan, Susanna Schuler, John T Watson, Sankan Nyanseor and 7 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Lauren E GentlesDivision of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Leanne KehoeDivision of Infectious Disease, Seattle Children's Hospital, Seattle, Washington, USA.
Katharine H D CrawfordDivision of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Kirsten LacombeDivision of Infectious Disease, Seattle Children's Hospital, Seattle, Washington, USA.
Jane DickersonDivision of Infectious Disease, Seattle Children's Hospital, Seattle, Washington, USA.
Caitlin WolfDivision of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Joanna YuanDivision of Infectious Disease, Seattle Children's Hospital, Seattle, Washington, USA.
Susanna SchulerDivision of Infectious Disease, Seattle Children's Hospital, Seattle, Washington, USA.
John T WatsonDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Sankan NyanseorDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Melissa Briggs-HagenDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Sharon SaydahDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Claire M MidgleyDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Kimberly PringleDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Helen ChuDivision of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Jesse D BloomDivision of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Janet A EnglundDivision of Infectious Disease, Seattle Children's Hospital, Seattle, Washington, USA.
Centers for Disease Control and Prevention · USSeattle Children's Hospital · USUniversity of Washington · USHoward Hughes Medical Institute · US

Funding

University of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4M
High-throughput experiments to guide influenza vaccine strain selectionR01AI127893 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2016 to 2020
$2.1M
Prospectively characterizing the functional and antigenic effects of mutations to viral entry proteinsR01AI141707 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2018 to 2022
$2.1M
NIAID NIH HHS R01 AI127893NIAID NIH HHS R01 AI141707NIGMS NIH HHS T32 GM007266
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicits an antibody response that targets several viral proteins including spike (S) and nucleocapsid (N); S is the major target of neutralizing antibodies. Here, we assess levels of anti-N binding antibodies and anti-S neutralizing antibodies in unvaccinated children compared with unvaccinated older adults following infection. Specifically, we examine neutralization and anti-N binding by sera collected up to 52 weeks following SARS-CoV-2 infection in children and compare these to a cohort of adults, including older adults, most of whom had mild infections that did not require hospitalization. Neutralizing antibody titers were lower in children than adults early after infection, but by 6 months titers were similar between age groups. The neutralizing activity of the children's sera decreased modestly from one to six months; a pattern that was not significantly different from that observed in adults. However, infection of children induced much lower levels of anti-N antibodies than in adults, and levels of these anti-N antibodies decreased more rapidly in children than in adults, including older adults. These results highlight age-related differences in the antibody responses to SARS-CoV-2 proteins and, as vaccines for children are introduced, may provide comparator data for the longevity of infection-elicited and vaccination-induced neutralizing antibody responses.

Indexed as

anti-nucleocapsid antibodieslongitudinal dynamicsneutralizing antibodiespediatric serologySARS-CoV-2

Identifiers

PMID35118481
PMCPMC8811949
OpenAlexW4210311096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.